Brief: Intellia Therapeutics Q1 Net Income USD -96.231 Million
11/05/2026 12:30
May 11 (Reuters) - Intellia Therapeutics Q1 collaboration revenue USD 15.048 million. Q1 operating expenses USD 115.58 million Q1 operating income USD -100.532 million Q1 basic EPS USD -0.81
Recent news on INTELLIA THERAPEUTICS
See all newsU.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Intellia rises after FDA grants fast-track status to its treatment for rare disease
Brief: Intellia Therapeutics Announces FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran (Lonvo-Z) For Hereditary Angioedema (Hae)